NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach: 2010 Revision. Geneva: World Health Organization; 2010.

Cover of Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access

Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach: 2010 Revision.

Show details

ANNEX KREFERENCES

1.
WHO; U.; UNICEF. Towards universal access: Scaling up priority hiv/aids interventions in the health sector. Progress report 2008. Geneva: 2008.
2.
WHO; UNAIDS; UNICEF. Towards universal access: Scaling up priority hiv/aids interventions in the health sector. Progress report 2009. Geneva: 2009.
3.
KIDS-ART-LINC Collaboration. Low risk of death, but substantial program attrition, in pediatric hiv treatment cohorts in sub-saharan africa. Journal of Acquired Immune Deficiency Syndromes. 2008;49(5):523–31. [PubMed: 18989227]
4.
WHO. Antiretroviral therapy for hiv infection in infants and children: Towards universal access. Recommendations for a public health approach. Geneva: World Health Organization; 2006. [PubMed: 23741772]
5.
Violari A, et al. Early antiretroviral therapy and mortality among hiv-infected infants. N Engl J Med. 2008;359(21):2233–44. [PMC free article: PMC2950021] [PubMed: 19020325]
6.
Gilks CF, et al. The who public-health approach to antiretroviral treatment against hiv in resource-limited settings. Lancet. 2006;368(9534):505–10. [PubMed: 16890837]
7.
WHO. Antiretroviral therapy for hiv infection in adults and adolescents in resource-limited settings: Towards universal access. Recommendations for a public health approach. Geneva: World Health Organization; 2010.
8.
WHO. Who recommendations on the diagnosis of hiv infection in infants and children. Geneva: World Health Organization; 2010.
9.
GRADE Working Group. Grading quality of evidence and strength of recommendation. BMJ. 2004;328 [PMC free article: PMC428525] [PubMed: 15205295]
10.
Guyatt GH, et al. Grade: An emerging consensus on rating quality of evidence and strength of recommendation. BMJ. 2008;336(7650):924–6. [PMC free article: PMC2335261] [PubMed: 18436948]
11.
WHO. The who handbook for guideline development. March 2008 ed. Geneva: 2008.
12.
Violari A, et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young hiv-infected infants: Evidence from the children with hiv early anti-retroviral therapy (cher) study; 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007; Sydney, Australia.
13.
Mphatswe W, et al. High frequency of rapid immunological progression in african infants infected in the era of perinatal hiv prophylaxis. AIDS. 2007;21(10):1253–61. [PubMed: 17545701]
14.
Prendergast A, et al. Randomized, controlled trial of 3 approaches to management of hiv-infected infants; 15th Conference onf Retrovirus and Opportunistic Infections; 2008; Boston, USA.
15.
WHO. Report of the who guideline review meeting to review recommendations on diagnosis of hiv infection in infants and children. World Health Organization; Geneva, Switzerland: 2009.
16.
WHO. Report recommendations of the who guideline review meeting to review ecommendations on the diagnosis of hiv infection in infants and children. World Health Organization; Geneva: 2008.
17.
Berk D, et al. Temporal trends in early clinical manifestations of perinatal hiv infection in a population-based cohort. JAMA. 2005;293:2221–31. [PubMed: 15886377]
18.
Cherutich P, et al. Optimizing paediatric hiv care in kenya: Challenges in early infant diagnosis. Bull World Health Organ. 2008;86(2):155–60. [PMC free article: PMC2647375] [PubMed: 18297171]
19.
UNICEF; S.W.a. Co-trimoxazole prophylaxis for hiv-exposed and hiv-infected infants and children. Practical approaches to implementation and scale up. 2010. [cited 2010; Available from: http://www​.who.int/hiv​/pub/paediatric/co-trimoxazole​/en/index.html.
20.
WHO. Revised principles and recommendations on hiv and infant feeding. Geneva: World Health Organization; 2010.
21.
WHO. Antiretroviral therapy for hiv infection in adults and adolescents, recommendations for a public health approach. Geneva: World Health Organization; 2010. [PubMed: 23741771]
22.
Lambert J, et al. Performance characteristics of hiv-1 culture and hiv-1 DNA and rna amplification assays for early diagnosis of perinatal hiv-1 infection. J Acquir Immune Defic Syndr. 2003;34(5):512–09. [PubMed: 14657763]
23.
Delamare C, et al. Hiv-1 rna detection in plasma for the diagnosis of infection in neonates. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(2):121–25. [PubMed: 9241110]
24.
Young N, et al. Early diagnosis of hiv-1-infected infants in thailand using rna and DNA pcr assays sensitive to non-b subtypes. J Acquir Immune Defic Syndr. 2000;24(5):401–07. [PubMed: 11035610]
25.
Nesheim S, et al. Quantitative rna testing for diagnosis of hiv-infected infants. J Acquir Immune Defic Syndr. 2003;32(2):192–95. [PubMed: 12571529]
26.
Horwood C, et al. Diagnosis of paediatric hiv infection in a primary health care setting with a clinical algorithm. Bull World Health Organ. 2003;81(12):858–66. [PMC free article: PMC2572386] [PubMed: 14997238]
27.
De Baets AJ, et al. Care and treatment of hiv-infected children in africa: Issues and challenges at the district hospital level. Pediatr Infect Dis J. 2007;26(2):163–73. [PubMed: 17259881]
28.
Peltier C, et al. Validation of 2006 who prediction scores for true hiv infection in children less than 18 months with a positive serological hiv test. PLoS One. 2009;4(4):e5312. [PMC free article: PMC2669178] [PubMed: 19390690]
29.
Jones SA, Sherman GG, Coovadia AH. Can clinical algorithms deliver an accurate diagnosis of hiv infection in infancy? Bull World Health Organ. 2005;83(7):559–60. [PMC free article: PMC2626291] [PubMed: 16175834]
30.
Brahmbhatt H, et al. Mortality in hiv-infected and uninfected children of hiv-infected and uninfected mothers in rural uganda. J Acquir Immune Defic Syndr. 2006;41(4):504–08. [PubMed: 16652060]
31.
Newell ML, et al. Mortality of infected and uninfected infants born to hiv-infected mothers in africa: A pooled analysis. Lancet. 2004;364(9441):1236–43. [PubMed: 15464184]
32.
Group, D.A.D.S. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in hiv-infected patients enrolled in the d: A: D study. Lancet. 2008;371:1417–26. [PMC free article: PMC2688660] [PubMed: 18387667]
33.
Various. Child survival series. The Lancet. 2003
34.
Tindyebwa D, et al., editors. ANECCA. Handbook on paediatric aids in africa. USAID; 2006.
35.
Bikaako-Kajura W, et al. Disclosure of hiv status and adherence to daily drug regimens among hiv-infected children in uganda. AIDS Behav. 2006;10(4 Suppl):S85–93. [PubMed: 16791525]
36.
Wiener L, et al. Disclosure of an hiv diagnosis to children: History, current research, and future directions. J Dev Behav Pediatr. 2007;28(2):155–66. [PMC free article: PMC2440688] [PubMed: 17435473]
37.
Sutcliffe CG, et al. Survival from 9 months of age among hiv-infected and uninfected zambian children prior to the availability of antiretroviral therapy. Clin Infect Dis. 2008;47(6):837–44. [PMC free article: PMC2753245] [PubMed: 18680417]
38.
Fassinou P, et al. Highly active antiretroviral therapies among hiv-1-infected children in abidjan, cote d'ivoire. AIDS. 2004;18(14):1905–13. [PubMed: 15353976]
39.
Dunn D. Short-term risk of disease progression in hiv-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: A meta-analysis. Lancet. 2003;362(9396):1605–11. [PubMed: 14630440]
40.
Dunn D, et al. Current cd4 cell count and the short-term risk of aids and death before the availability of effective antiretroviral therapy in hiv-infected children and adults. J Infect Dis. 2008;197(3):398–404. [PubMed: 18248303]
41.
Little K, et al. Disease progression in children with vertically-acquired hiv infection in sub-saharan africa: Reviewing the need for hiv treatment. Curr HIV Res. 2007;5(2):139–53. [PubMed: 17346131]
42.
Chintu C, et al. Co-trimoxazole as prophylaxis against opportunistic infections in hiv-infected zambian children (chap): A double-blind randomised placebo-controlled trial. Lancet. 2004;364(9448):1865–71. [PubMed: 15555666]
43.
Committee, C.C.C.f.K.C.k.A.a.W. Markers for predicting mortality in untreated hiv-infected children in resource-limited settings: A meta-analysis. AIDS. 2008;22(1):97–105. [PubMed: 18090397]
44.
WHO. Preferred antiretroviral medicines for treating and preventing hiv infection in younger children. Report of the who paediatric anti-retroviral working group. WHO; Geneva: 2008.
45.
Corbett A, et al. Pharmacokinetics between trade and generic liquid and split tablet formulations of lamivudine, stavudine, and nevirapine in hiv-infected malawian children; International Conference on Antimicrobal Agents and Chemotherapy; 2005; Washington, DC, USA.
46.
King JR, et al. Antiretroviral pharmacokinetics in the paediatric population: A review. Clin Pharmacokinet. 2002;41(14):1115–33. [PubMed: 12405863]
47.
Sutcliffe CG, et al. Effectiveness of antiretroviral therapy among hiv-infected children in sub-saharan africa. Lancet Infect Dis. 2008;8(8):477–89. [PubMed: 18652994]
48.
Patel K, et al. Long-term effects of highly active antiretroviral therapy on cd4+ cell evolution among children and adolescents infected with hiv: 5 years and counting. Clin Infect Dis. 2008;46(11):1751–60. [PMC free article: PMC3154876] [PubMed: 18426371]
49.
Eley B, et al. Initial experience of a public sector antiretroviral treatment programme for hiv-infected children and their infected parents. S Afr Med J. 2004;94(8):643–6. [PubMed: 15352588]
50.
Gortmaker SL, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with hiv-1. N Engl J Med. 2001;345(21):1522–8. [PubMed: 11794218]
51.
Kline MW, et al. Comprehensive pediatric human immunodeficiency virus care and treatment in constanta, romania: Implementation of a program of highly active antiretroviral therapy in a resource-poor setting. Pediatr Infect Dis J. 2004;23(8):695–700. [PubMed: 15295217]
52.
Puthanakit T, et al. Efficacy of highly active antiretroviral therapy in hiv-infected children participating in thailand's national access to antiretroviral program. Clin Infect Dis. 2005;41(1):100–7. [PubMed: 15937769]
53.
Lockman S, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356(2):135–47. [PubMed: 17215531]
54.
NIAID, N.I.o.A.a.I.D., National Institute of Health. Bulletin: Ritonavir-boosted lopinavir proves superior to nevirapine in hiv-infected infants who received single-dose nevirapine at birth. 2009
55.
Palumbo P, et al. Nevirapine (nvp) vs lopinavir-ritonavir (lpv/r)-based antiretroviral therapy (art) in single dose nevirapine (sdnvp)-exposed hiv-infected infants: Preliminary results from the impaact p1060 trial; 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2009; Capetown, South Africa.
56.
Coovadia A, Abrams E, Strehlau R, Martens L, Sherman G, Meyers T, Kuhn L., NEVEREST Study Team. Randomized clinical trial of switching to nevirapine-based therapy for infected children exposed to nevirapine prophylaxis. IAS; Cape Town: 2009.
57.
Handforth J, Sharland M. Triple nucleoside reverse transcriptase inhibitor therapy in children. Paediatr Drugs. 2004;6(3):147–59. [PubMed: 15170362]
58.
Arribas R. The rise and fall of triple nucleoside reverse transcriptase inhibitor (nrti) regimens. J Antimicrob Chemother. 2004;54(3):587–92. [PubMed: 15282236]
59.
Gulick RM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of hiv-1 infection. N Engl J Med. 2004;350(18):1850–61. [PubMed: 15115831]
60.
Staszewski S, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive hiv-infected adults: A randomized equivalence trial. Jama. 2001;285(9):1155–63. [PubMed: 11231744]
61.
Bang LM, Scott LJ. Emtricitabine: An antiretroviral agent for hiv infection. Drugs. 2003;63(22):2413–24. discussion 25-6. [PubMed: 14609348]
62.
Saez-Llorens X, et al. Long-term safety and Efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects. Pediatrics. 2008;121(4):e827–35. [PubMed: 18332076]
63.
European paediatric lipodystrophy group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in hiv-infected children in europe. AIDS. 2004;18(10):1443–51. [PubMed: 15199321]
64.
Van Dyke R, et al. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in hiv-infected children. J Infect Dis. 2008;198(11):1599–608. [PMC free article: PMC2737265] [PubMed: 19000014]
65.
Green H, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007;21(8):947–55. [PubMed: 17457088]
66.
D: A: D study group. Use of nucleaoside reverse transcriptase inhibitors and risk of myocardial infarction in hiv-infected patients enrolled in the d: A: D study. Lancet. 2008;371:1417–26. [PMC free article: PMC2688660] [PubMed: 18387667]
67.
Lundgren J, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in hiv-infected patients enrolled in th esmart study; XVII international AIDS Conference; 2008; Mexico City.
68.
Benson C, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: Results from actg a5001; 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
69.
Cutrell A, et al. Is abacavir-containing combination antiretroviral therapy associated with myocardial infaction? No associatino identified in pooled summary of 54 clinical trials; XVII International AIDS Conference; 2008; Mexico City.
70.
Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46(3):716–23. [PMC free article: PMC127499] [PubMed: 11850253]
71.
Paediatric european network for treatment of aids (penta) Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with hiv-1 who have not previously been treated: The penta 5 randomised trial. Lancet. 2002;359(9308):733–40. [PubMed: 11888583]
72.
Gallant JE, et al. Tenofovir df, emtricitabine, and efavirenz vs. Zidovudine, lamivudine, and efavirenz for hiv. N Engl J Med. 2006;354(3):251–60. [PubMed: 16421366]
73.
Verhelst D, et al. Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am J Kidney Dis. 2002;40(6):1331–3. [PubMed: 12460055]
74.
Karras A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36(8):1070–3. [PubMed: 12684922]
75.
Schaaf B, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37(3):e41–3. [PubMed: 12884188]
76.
Giacomet V, et al. A 12 month treatment with tenofovir does not impair bone mineral accrual in hiv-infected children. J Acquir Immune Defic Syndr Hum Retrovirol. 2005;40(4):448–50. [PubMed: 16280700]
77.
Hazra R, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric hiv infection. Pediatrics. 2005;116(6):e846–54. [PubMed: 16291735]
78.
Purdy J, et al. Decreased bone mineral density with off-label use of tenofovir in children andadolescents infected with human immunodeficiency virus. J Pediatr. 2008;152(4):582–84. [PMC free article: PMC2390888] [PubMed: 18346519]
79.
Aurpibul L, et al. Haematological changes after switching from stavudine to zidovudine in hiv-infected children receiving highly active antiretroviral therapy. HIV Med. 2008;9(5):317–21. [PubMed: 18331562]
80.
Kline MW, et al. A phase i/ii evaluation of stavudine (d4t) in children with human immunodeficiency virus infection. Pediatrics. 1995;96(2 Pt 1):247–52. [PubMed: 7630678]
81.
Kline MW, et al. A pilot study of combination therapy with indinavir, stavudine (d4t), and didanosine (ddi) in children infected with the human immunodeficiency virus. J Pediatr. 1998;132(3 Pt 1):543–6. [PubMed: 9544920]
82.
Pollard RB, et al. A phase ii randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 cd4 cells who were antiretroviral naive (actg 298) AIDS Res Hum Retroviruses. 2002;18(10):699–704. [PubMed: 12167276]
83.
Hoggard PG, et al. Effects of drugs on 2'.3'-dideoxy-2'.3'-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother. 1997;41(6):1231–6. [PMC free article: PMC163892] [PubMed: 9174176]
84.
Ena J, et al. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in hiv-infected patients. Int J STD AIDS. 2003;14(11):776–81. [PubMed: 14624743]
85.
Keiser P, et al. Comparison of nevirapine-and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: A cohort study. HIV Clin Trials. 2002;3(4):296–303. [PubMed: 12187503]
86.
Keiser P, et al. Comparison of Efficacy of efavirenz and nevirapine: Lessons learned for cohort analysis in light of the 2nn study. HIV Clin Trials. 2003;4(5):358–60. [PubMed: 14583852]
87.
Law WP, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the hiv-nat cohort, thailand, 1996-2001. AIDS. 2003;17(15):2191–9. [PubMed: 14523276]
88.
Martin-Carbonero L, et al. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4(2):115–20. [PubMed: 12671779]
89.
Moyle GJ. Nnrti choice: Has 2nn changed our practice? AIDS Read. 2003;13(7):325–8. [PubMed: 12889450]
90.
van Leth F, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2nn study. Lancet. 2004;363(9417):1253–63. [PubMed: 15094269]
91.
Teglas JP, et al. Tolerance of efavirenz in children. AIDS. 2001;15(2):241–3. [PubMed: 11216933]
92.
Ren Y, et al. Effect of rifampicin on efavirenz pharmacokinetics in hiv-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2009;50(5):439–43. [PubMed: 19223781]
93.
Cohn S, Hitti J. Issues regarding use of hormonal contraceptives in clinical trials of antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol. 2005;(38 Suppl 1):S21–22. [PubMed: 15867605]
94.
Cohn SE, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: Effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther. 2007;81(2):222–27. [PubMed: 17192768]
95.
Watts D, et al. Safety and tolerability of depot medroxyprogesterone acetate among hiv-infected women on antiretroviral therapy: Actg a5093. Contraception. 2008;77(2):84–90. [PMC free article: PMC2424313] [PubMed: 18226670]
96.
Nanda K, et al. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertility and Sterility. 2008;90(4):965–71. [PubMed: 17880953]
97.
Blanche S, et al. Pharmacokinetics, safety and Efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS. 2009;23(15):2005–13. [PubMed: 19724191]
98.
Braitstein P, et al. Mortality of hiv-1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet Infect Dis. 2006;367(9513):817–24. [PubMed: 16530575]
99.
Coutinho AM, et al. Utility of routine viral load, cd4 cell count, and clinical monitoring among hiv-infected adults in uganda: A randomized trial; 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, USA.
100.
Moore D, et al. Cd4+ t-cell count monitoring does not accurately identify hiv-infected adults with virologic failure receiving anti-retroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol. 2008;49(5):477–84. [PubMed: 18989232]
101.
DART, T.T. Routine versus clinically driven laboratory monitoring of hiv antiretroviral therapy in africa (dart): A randomised non-inferiority trial. Lancet. 2010;375(9709):123–31. [PMC free article: PMC2805723] [PubMed: 20004464]
102.
WHO. Use of antiretroviral drugs for treating pregnant women and preventing hiv infection in infants. Geneva: World Health Organization; 2010. [PMC free article: PMC3535284] [PubMed: 23293399]
103.
Bolton-Moore C, et al. Clinical outcomes and cd4 cell response in children receiving antiretroviral therapy at primary health care facilities in zambia. JAMA. 2007;298(16):1888–99. [PubMed: 17954540]
104.
Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: More answers, more questions. J Antimicrob Chemother. 2005 [PubMed: 16354748]
105.
Hirsch HH, et al. Immune reconstitution in hiv-infected patients. Clin Infect Dis. 2004;38(8):1159–66. [PubMed: 15095223]
106.
Boulware D, Callens S, Pahwa S. Pediatric hiv immune reconstitution inflammatory syndrome (iris) Curr Opin HIV AIDS. 2008;3(4):461–67. [PMC free article: PMC2680317] [PubMed: 19373006]
107.
Kilborn T, Zampoli M. Immune reconstitution inflammatory syndrome after initiating highly active antiretroviral therapy in hiv-infected children. Pediatr Radiol. 2009;39(6):569–74. [PubMed: 19277634]
108.
Jevtovic DJ, et al. The prevalence and risk of immune restoration disease in hiv-infected patients treated with highly active antiretroviral therapy. HIV Med. 2005;6(2):140–3. [PubMed: 15807721]
109.
Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in hiv-infected children. Int J Tuberc Lung Dis. 2007;11(4):417–23. [PubMed: 17394688]
110.
Tangsinmankong N, et al. Varicella zoster as a manifestation of immune restoration disease in hiv-infected children. J Allergy Clin Immunol. 2004;113(4):742–6. [PubMed: 15100682]
111.
Nuttall JJ, et al. Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: A case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis J. 2004;23(7):683–5. [PubMed: 15247614]
112.
Puthanakit T, et al. Immune reconstitution syndrome due to bacillus calmette-guerin after initiation of antiretroviral therapy in children with hiv infection. Clin Infect Dis. 2005;41(7):1049–52. [PMC free article: PMC1924528] [PubMed: 16142674]
113.
Puthanakit T, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J. 2006;25(1):53–58. [PMC free article: PMC1924530] [PubMed: 16395104]
114.
McComsey GA, Leonard E. Metabolic complications of hiv therapy in children. AIDS. 2004;18(13):1753–68. [PubMed: 15316336]
115.
Sharland M, et al. Penta guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004;5 Suppl 2:61–86. [PubMed: 15239717]
116.
Haas DW. Pharmacogenomics and hiv therapeutics. J Infect Dis. 2005;191(9):1397–400. [PubMed: 15809895]
117.
Verweel G, et al. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics. 2002;109(2):E25. [PubMed: 11826235]
118.
Lindsey JC, et al. Treatment-mediated changes in human immunodeficiency virus (hiv) type 1 rna and cd4 cell counts as predictors of weight growth failure, cognitive decline, and survival in hiv-infected children. J Infect Dis. 2000;182(5):1385–93. [PubMed: 11010839]
119.
McCoig C, et al. Effect of combination antiretroviral therapy on cerebrospinal fluid hiv rna, hiv resistance, and clinical manifestations of encephalopathy. J Pediatr. 2002;141(1):36–44. [PubMed: 12091849]
120.
Mofenson LM, et al. The relationship between serum human immunodeficiency virus type 1 (hiv-1) rna level, cd4 lymphocyte percent, and long-term mortality risk in hiv-1-infected children. National institute of child health and human development intravenous immunoglobulin clinical trial study group. J Infect Dis. 1997;175(5):1029–38. [PubMed: 9129063]
121.
Florence E, et al. The role of non-viral load surrogate markers in hiv-positive patient monitoring during antiviral treatment. Int J STD AIDS. 2004;15(8):538–42. [PubMed: 15307965]
122.
Renaud-Théry F, et al. Use of antiretroviral therapy in resource-limited countries in 2006: Distribution and uptake of first- and second-line regimens. AIDS. 2007;21(Suppl4):S89–95. [PubMed: 17620758]
123.
Renaud-Théry F, et al. Use of antiretroviral therapy in resource-limited countries in 2007: Up-take of 2nd-line and paediatric treatment stagnant; XVII International AIDS Conference; 2008; Mexico City.
124.
Sungkanuparph S, et al. Options for a second-line antiretroviral regimen for hiv type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007;44(3):447–52. [PubMed: 17205457]
125.
Puthanakit T, et al. Hiv-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med. [PubMed: 20345882]
126.
Floren LC, et al. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric aids clinical trials group protocol 377. Pediatrics. 2003;112(3 Pt 1):e220–7. [PubMed: 12949316]
127.
Pelton SI, et al. Switch from ritonavir to indinavir in combination therapy for hiv-1-infected children. Clin Infect Dis. 2005;40(8):1181–7. [PubMed: 15791520]
128.
Saez-Llorens X, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22(3):216–24. [PubMed: 12634581]
129.
Averbuch D, et al. Diminished selection for thymidine-analog mutations associated with the presence of m184v in ethiopian children infected with hiv subtype c receiving lamivudine-containing therapy. Pediatr Infect Dis J. 2006;25(11):1049–56. [PubMed: 17072129]
130.
Campbell TB, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant hiv-1 infection. Clin Infect Dis. 2005;41(2):236–42. [PubMed: 15983922]
131.
Walmsley S, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of hiv infection. N Engl J Med. 2002;346(26):2039–46. [PubMed: 12087139]
132.
Kovacs A, et al. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive hiv disease and complete or partial viral load response. J Infect Dis. 2005;192(2):296–302. [PubMed: 15962224]
133.
Chintu C, Mwaba P. Tuberculosis in children with human immunodeficiency virus infection. Int J Tuberc Lung Dis. 2005;9(5):477–84. [PubMed: 15875917]
134.
Geoghagen M, et al. Tuberculosis and hiv co-infections in jamaican children. West Indian Med J. 2004;53(5):339–45. [PubMed: 15675501]
135.
Lawn SD, et al. Impact of hiv infection on the epidemiology of tuberculosis in a periurban community in south africa: The need for age-specific interventions. Clin Infect Dis. 2006;42(7):1040–7. [PubMed: 16511773]
136.
Ispas D, et al. Evidence for tuberculous infection in romanian hiv-positive children by enzyme-linked immunosorbent assay. Pediatr AIDS HIV Infect. 1996;7(2):98–102. [PubMed: 11361487]
137.
Jeena PM, et al. Impact of hiv-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in durban, south africa. Int J Tuberc Lung Dis. 2002;6(8):672–8. [PubMed: 12150478]
138.
Palme IB, et al. Risk factors for human immunodeficiency virus infection in ethiopian children with tuberculosis. Pediatr Infect Dis J. 2001;20(11):1066–72. [PubMed: 11734713]
139.
Ramirez-Cardich ME, et al. Clinical correlates of tuberculosis co-infection in hiv-infected children hospitalized in peru. Int J Infect Dis. 2006 [PubMed: 16540360]
140.
WHO. Guidelines for an integrated approach to the nutritional care of hiv-infected children (6 months-14 years). Handbook. Preliminary version for country introduction. Geneva: World Health Organization; 2009.
141.
WHO. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: 2006. [PubMed: 17044200]
142.
WHO. WHO report on TB medicines for children. Geneva, Switzerland: 2008. Report of the meeting on tb medicines for children who headquarters.
143.
Zar HJ, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with hiv: Randomised controlled trial. BMJ. 2007;334(7585):136. [PMC free article: PMC1779846] [PubMed: 17085459]
144.
WHO. WHO Technical Report Series. WHO; Geneva: 2008. The second meeting of the subcommittee of the expert committee on the selection and use of essential medicines; 29 september to 3 october 2008; draft report.
145.
Madhi S, et al. Lack of Efficacy of primary isoniazid (inh) prophylaxis in increasing tuberculosis (tb) free survival in hiv-infected (hiv +) south african children; 48th Annua Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC™) 46th Annual Meeting of the Infectious Diseases Society of America; 2008; Washington, D.C., USA.
146.
WHO. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with hiv in resource-constrained settings. Geneva: World Health Organization; 2010.
147.
Akolo C, et al. Treatment of latent tuberculosis infection in hiv infected persons. Cochrane Database Syst Rev. 2010;(1):CD000171. [PubMed: 20091503]
148.
Grimwade K, Swingler GH. Cotrimoxazole prophylaxis for opportunistic infections in children with hiv infection. Cochrane Database Syst Rev. 2006;(1):CD003508. [PubMed: 16437457]
149.
Nunn A, et al. Role of co-trimoxazole prophylaxis in reducing mortality in hiv infected adults being treated for tuberculosis: Randomised clinical trial. BMJ. 2008;337(a257) [PMC free article: PMC2656923] [PubMed: 18617486]
150.
Grimwade K, et al. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural south africa. AIDS. 2005;19(2):163–8. [PubMed: 15668541]
151.
Marais B, Gie R, Hesseling A, Schaaf H, Lombard C, Enarson D, Beyers N. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics. 2006;118:1350–9. [PubMed: 17079536]
152.
Van Rheenen P. The use of a paediatric tuberculosis score chart in an hiv-endemic area. Trop Med Int Health. 2002;7:435–4. [PubMed: 12000653]
153.
Connell T, Johannisen C, et al. Detection of tuberculosis in hiv-infected children using an enzyme-linked immunospot assay. AIDS. 2009;23:961–9. [PMC free article: PMC4849554] [PubMed: 19287300]
154.
Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan A, Lalvani A. Diagnosis of tuberculosis in south african children with a t-cell-based assay: A prospective cohort study. Lancet. 2004;364:2196–203. [PubMed: 15610806]
155.
Mandalakas A, Hesseling A, Chegou N, et al. High level of discordant igra results in hiv-infected adults and children. Int J Tuberc Lung Dis. 2008;12:417–23. [PubMed: 18371268]
156.
Patel A, et al. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in india who are coinfected with tuberculosis and hiv-1. J Acquir Immune Defic Syndr. 2004;37(1):1166–69. [PubMed: 15319677]
157.
Finch CK, et al. Rifampin and rifabutin drug interactions: An update. Arch Intern Med. 2002;162(9):985–92. [PubMed: 11996607]
158.
Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (haart) in adults with tuberculosis: Current status. Int J Tuberc Lung Dis. 2005;9(3):248–57. [PubMed: 15786886]
159.
Van Cutsem G, et al. Tb/hiv coinfected patients on rifampicin-containing treatment have equivalent art treatment outcomes and concurrent use of nevirapine is not associated with increased hepatotoxicity, abstract wepp0303; Third International AIDS Conference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro, Brazil.
160.
Barlow-Mosha L, M P, Parsons T, Ajuna P, Lutajjumwa M, Musoke B, Bagenda D, Mubiru M, Mirochnick M., MUJHU Intl Leadership Award (EGPAF) Team. Nevirapine concentrations in hiv-infected ugandan children on adult fixed-dose combination tablet art, with and without rifampicin-based treatment for active m. Tuberculosis infection; 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal.
161.
Prasitsuebsai W, C T, Capparelli E, Vanprapar N, Lapphra K, Chearskul P, Chokephaibulkit K. Pharmacokinetics of nevirapine when co-administered with rifampin in hiv-infected thai children with tb; 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal.
162.
Munderi P, et al. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not refected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in hiv-infected ugandan adults with low cd4 cell counts. HIV Med. 2010 [PubMed: 20136661]
163.
Reid A, et al. Severe renal dysfunction and risk factors associated with renal impairment in hiv-infected adults in africa initiating antiretroviral therapy. Clin Infect Dis. 2008;46(8):1271–81. [PubMed: 18444867]
164.
Baleta A. Trial finds simultaneous hiv/tuberculosis treatment beneficial. Lancet Infect Dis. 2008;8(11):669. [PubMed: 18992400]
165.
Ren Y, et al. Effect of rifampicin on lopinavir pharmacokinetics in hiv-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008;57(5):566–69. [PubMed: 18197120]
166.
Jarvis B, Faulds D. Nelfinavir. A review of its therapeutic Efficacy in hiv infection. Drugs. 1998;56(1):147–67. [PubMed: 9664204]
167.
Niemi M, et al. Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet. 2003;42(9):819–50. [PubMed: 12882588]
168.
Hesseling A, et al. Disseminated bacille calmette-guérin disease in hiv-infected south african infants. Bulletin of the World Health Organization. 2009;(87) [PMC free article: PMC2704039] [PubMed: 19649364]
169.
Meintjes G, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516–23. [PMC free article: PMC2804035] [PubMed: 18652998]
170.
W.H. Organization, editor. WHO. Vitamin a supplements: A guide to their use in the treatment and prevention of vitamin a Deficiency and xerophthalmia. Second edition. Geneva, Switzerland: 1997.
171.
WHO. Management of serious malnutrition: A manual for physicians and other senior health workers. Geneva, Switzerland: World Health Organization; 1998.
172.
W.H.O. WHO/FCH/CAH/00.1, editor. WHO. Management of a child with a serious infection or malnutrition: Guidelines for the care at the first-referral level in developing countries. Geneva, Switzerland: World Health Organization; 2000.
173.
W.H. Organization, editor. WHO. HIV infant feeding: A guide for health-care managers and supervisors. Geneva, Switzerland: 2003.
174.
W.H. Organization, editor. WHO. Hiv infant feeding: Guidelines for decision-makers. Geneva, Switzerland: 2003.
175.
WHO, editor. WHO. Nutrient requirements for people living with hiv/aids Report of a technical consultation. World health organization, geneva; Geneva, Switzerland: may 13-15, 2003. 2003.
176.
Chandra R, Kumari S. Nutrition and immunity: An overview. J Nutr. 1994;124:1433S–35S. [PubMed: 8064398]
177.
Arpadi SM, et al. Growth velocity, fat-free mass and energy intake are inversely related to viral load in hiv-infected children. J Nutr. 2000;130(10):2498–502. [PubMed: 11015480]
178.
Callens S, et al. SARA team. Mortality and associated factors after initiation of pediatric antiretroviral treatment in the democratic republic of the congo. Pediatr Infect Dis J. 2009;28:35–40. [PubMed: 19057457]
179.
Rollins N, van den Broek J, Kindra G, Pent M, Bennish M. The effect of nutritional support on weight gain of hiv-infected children with prolonged diarrhea. Acta Paediatr. 2007;96:65–8. [PubMed: 17187606]
180.
Batterham M. Investigating heterogeneity in studies of resting energy expenditure in persons with hiv/aids: A meta-analysis. Am J Clin Nutr. 2005;81:702–13. [PubMed: 15755842]
181.
Chang E, Sekhar R, Patel S, Balasubramanyam A. Dysregulated energy expenditure in hiv-infected patients: A mechanistic review. Clin Infect Dis. 2007;44:1509–17. [PubMed: 17479951]
182.
Henderson R, Talusan K, Hutton N, Yolken R, Caballero B. Resting energy expenditure and body composition in children with hiv infection. J Acquir Immune Defic Syndr Hum Retrovir. 1998;19:150–7. [PubMed: 9768624]
183.
Johann-Liang R, et al. Energy balance, viral burden, insulin-like growth factor-1, interleukin-6 and growth impairment in children infected with human immunodeficiency virus. AIDS. 2000;14(6):683–90. [PubMed: 10807191]
184.
Mahlungulu S, Grobler L, Visser M, Volmink J. Nutritional interventions of reducing morbidity and mortality in people with hiv. Cochrane Database of Systematic Review. 2007;4:Art no. CD003650. [PubMed: 17636766]
185.
Irlam J, Visser M, Rollins N, Siegfried N. Micronutrient supplementation in children and adults with hiv infection. Cochrane Database of Systematic Review. 2005;4:Art no. CD003650. [PubMed: 16235333]
186.
Fawzi W, Msmanga G, Spiegelman D, Urassa E, McGrath N, Mwakagile D, et al. Randomised trial of effects of vitamin supplementation on pregnancy outcomes and t cell counts in hiv-1 infected women in tanzania. Lancet. 1998;351:1477–82. [PubMed: 9605804]
187.
Coutsoudis A, et al. The effects of vitamin a supplementation on the morbidity of children born to hiv-infected women. Am J Public Health. 1995;85(8 Pt 1):1076–81. [PMC free article: PMC1615817] [PubMed: 7625499]
188.
Fawzi W, Mbise R, Hertzmark E, Fataki M, Herrera M, Ndossi G, et al. A randomized trial of vitamin a supplements in relation to mortality among hiv-infected and uninfected children in tanzania. Ped Infect Dis. 1999;18:127–33. [PubMed: 10048684]
189.
Fawzi W, Mbise R, Spiegelman D, Fataki M, Hertzmark E, Ndossi G. Vitamin a supplements and diarrhoeal and respiratory tract infections among children in dar es salaam, tanzania. J Pediatr. 2000;137:660–7. [PubMed: 11060532]
190.
Semba R, et al. Effect of periodic vitamin a supplementation on mortality and morbidity of hiv-infected children in uganda: A controlled clinical trial. Nutr. 2005;21:25–31. [PubMed: 15661475]
191.
WHO. Integrated management of childhood illness for high hiv setting. Geneva: World Health Organization; 2008.
192.
Bobat R, Coovadia H, Stephen C, Naidoo K, McKerrow N, Black R, Moss W. Safety and Efficacy of zinc supplementation for children with hiv-1 infection in south africa: A randomised double-blind placebo-controlled trial. Lancet. 2005;366:1862–7. [PubMed: 16310552]
193.
Chhagan M, van den Broeck J, Luabeya K, Mpontshane N, Tucker K, Bennish M. Effect of micronutrient supplementation on diarrhoeal disease among stunted children in rural south africa. Eur J Nutr. 2009;63:850–7. [PMC free article: PMC2705811] [PubMed: 19174830]
194.
Luabeya K, et al. Zinc or multiple micronutrient supplementation to reduce diarrhea and respiratory disease in south african children: A randomized controlled trial. PLoS ONE. 2007;2:e541. [PMC free article: PMC1891438] [PubMed: 17593956]
195.
De Onis M, editor. WHO; D.o.N.f.H.a.D. Who child growth standards: Length/height-for-age, weight-for-age, weight-for-length, weight -for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization; 2006.
196.
Mburu A, Thurnham D, Mwaniki D, Muniu E, Alumasa F, de Wagt A. The influence and benefits of controlling for inflammation on plasmsa ferritin and hemoglobin responses following a multi-micronutrient supplement in apparently healthy hiv + kenyan adults. J Nutr. 2008;138:613–19. [PubMed: 18287375]
197.
Thurnham D, Mburu A, Mwaniki D, Muniu E, Alumasa F, de Wagt A. Using plasma acute-phaase protein concentrations to interpret nutritional biomarkers in apparently healthy hiv-1 seropositive kenyan adults. J Nutr. 2008;100:174–82. [PubMed: 18177514]
198.
Fergusson P, Chinkhumba J, Grijalva-Eternod C, Banda T, Mkangama C, Tomkins A. Nutritional recovery in hiv-infected and hiv-uninfected children with severe acute malnutrition. Arch Dis Child. 2009;94:512–16. [PubMed: 18977785]
199.
Fergusson P, Tomkins A. Hiv prevalence and mortality among children undergoing treatment for severe acute malnutrition in sub-saharan africa: A systematic review and meta-analysis. Trans Royal Soc Trop Med Hyg. 2009;103:541–48. [PubMed: 19058824]
200.
WHO. Management of severe malnutrition: A manual for physicians and other senior health workers. World Health Organisation; Geneva, Switzerland: 1999.
201.
Heikens GT, et al. Case management of hiv-infected severely malnourished children: Challenges in the area of highest prevalence. The Lancet. 2008;371(9620):1305–07. [PubMed: 18406865]
202.
de Martino M, et al. Puberty in perinatal hiv-1 infection: A multicentre longitudinal study of 212 children. AIDS. 2001;15(12):1527–34. [PubMed: 11504985]
203.
WHO. Antiretroviral therapy for hiv infection in adults and adolescents in resource-limited settings: Towards universal access: Recommendations for a public health approach. Geneva: World Health Organization; 2006.
204.
Dodds S, et al. Retention, adherence, and compliance: Special needs of hiv-infected adolescent girls and young women. Journal of Adolescent Health. 2003;33S:39–45. [PubMed: 12888286]
205.
WHO. More positive living: Strengthening the health sector response to young people living with hiv. Geneva: World Health Organization; 2008. p. 15.
206.
Reddi A, SC L. Antiretroviral therapy adherence in children: Outcomes from africa. AIDS. 2008;22(7):906–7. [PubMed: 18427213]
207.
Simoni J, et al. Adherence to antiretroviral therapy for pediatric hiv infection: A qualitative systematic review with recommendations for research and clinical management. Pediatrics. 2007;119(6):1371–83. [PubMed: 17533177]
208.
Vreeman R, et al. A systematic review of pediatric adherence to antiretroviral therapy in low- and middle-income countries. Pediatr Infect Dis J. 2008;(8):686–91. [PubMed: 18574439]
209.
Saitoh A, et al. Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired hiv infection. Pediatrics. 2008;121:e513–21. [PubMed: 18310171]
210.
Gibb DM, et al. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the penta 5 trial. Pediatr Infect Dis J. 2003;22(1):56–62. [PubMed: 12544410]
211.
Dolezal C, et al. The reliability of reports of medical adherence from children with hiv and their adult caregivers. J Pediatr Psychol. 2003;28(5):355–61. [PubMed: 12808012]
212.
Ledergerber B, et al. Predictors of trend in cd4-positive t-cell count and mortality among hiv-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364(9428):51–62. [PubMed: 15234856]
213.
Prado JG, et al. Hiv type 1 fitness evolution in antiretroviral-experienced patients with sustained cd4+ t cell counts but persistent virologic failure. Clin Infect Dis. 2005;41(5):729–37. [PubMed: 16080097]
214.
Nicastri E, et al. Clinical outcome after 4 years follow-up of hiv-seropositive subjects with incomplete virologic or immunologic response to haart. J Med Virol. 2005;76(2):153–60. [PubMed: 15834865]
215.
Kaplan SS, et al. Longitudinal assessment of immune response and viral characteristics in hiv-infected patients with prolonged cd4 (+)/viral load discordance. AIDS Res Hum Retroviruses. 2005;21(1):13–6. [PubMed: 15665640]
216.
Brigido L, et al. Cd4+ t-cell recovery and clinical outcome in hiv-1-infected patients exposed to multiple antiretroviral regimens: Partial control of viremia is associated with favorable outcome. AIDS Patient Care STDS. 2004;18(4):189–98. [PubMed: 15142349]
217.
Deeks SG, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant hiv-1 infection. J Infect Dis. 2005;192(9):1537–44. [PubMed: 16206068]
218.
Tindyebwa D, et al. African network for the care of children affected by aids. Handbook on paediatric aids in africa. ANECCA, editor. Kampala, Uganda: 2004.
219.
Lee E, et al. Breast-milk shedding of drug-resistant hiv-1 subtype c in women exposed to single-dose nevirapine. J. Infect. Dis. 2005;192:1260–64. [PubMed: 16136470]
220.
Moorthy A, et al. Nevirapine resistance and breast-milk hiv transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype c hiv-infected infants. PLoS One. 2009;4:e4096. [PMC free article: PMC2606064] [PubMed: 19119321]
221.
Chaix M, et al. Impact of nevirapine (nvp) plasma concentration on selection of resistant virus in mothers who received single-dose nvp to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob. Agents Chemother. 2007;51:896–901. [PMC free article: PMC1803117] [PubMed: 17178792]
222.
Flys T, et al. Nevirapine resistance in women and infants after first versus repeated use of single dose nevirapine for prevention of hiv-1 vertical transmission. J Infect Dis. 2008;198(4):465–69. [PMC free article: PMC2640946] [PubMed: 18582198]
223.
Bedri A, et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent hiv transmission via breastfeeding in ethiopia, india, and uganda: An analysis of three randomised controlled trials. Lancet. 2008;372(9635):300–13. [PubMed: 18657709]
224.
Lidstrom J, et al. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were hiv-infected in utero. AIDS. 2010;24(3):381–6. [PMC free article: PMC3063063] [PubMed: 19996936]
225.
Machado DM, et al. Analysis of hiv- type 1 protease and reverse transcriptase in brazilian children failing highly active anti-retroviral therapy (haart) Sao Paulo: Rev Inst Med Trop. 2005;47(1):1–5. [PubMed: 15729467]
226.
Arrivé E, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of hiv-1: A meta-analysis. International Journal of Epidemiology. 2007;36(5):1009–21. [PubMed: 17533166]
227.
Eshleman SH, et al. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (pediatric aids clinical trials group 377) J Infect Dis. 2001;183(12):1732–8. [PubMed: 11372025]
228.
Bennett DE, et al. The world health organization's global strategy for prevention and assessment of hiv drug resistance. Antivir Ther. 2008;13 Suppl 2:1–13. [PubMed: 18578063]
229.
Richman D, Morton S, Wrin T, et al. The prevalence of antiretroviral drug resistance in the united states. AIDS. 2004;18:1393–401. [PubMed: 15199315]
230.
Coffin J. Hiv population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483–89. [PubMed: 7824947]
231.
Jordan M, Bennett D, Bertagnolio S, Gilks C, Sutherland D. World health organization surveys to monitor hiv drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008;13 Suppl 2:15–23. [PubMed: 18575188]
232.
Arrive E, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of hiv-1: A meta-analysis. Int J Epidemiol. 2007;36:1009–21. [PubMed: 17533166]
233.
Eshleman S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of malawian newborns. AIDS. 2005;19:2167–69. [PubMed: 16284468]
234.
Eshleman SH, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent hiv-1 vertical transmission (hivnet 012) AIDS. 2001;15(15):1951–7. [PubMed: 11600822]
235.
Hunt G, et al. Development of drug resistance among a cohort of hiv-infected infants exposed to nevirapine for prevention of mother-to-child transmission initiating pi-based art in south africa; 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
236.
Ngo-Giang-Huong N, et al. Zidovudine prophylaxis and emergence of nevirapine resistance at 6 weeks in perinatally hiv-infected infants exposed to intra-partum or newborn nevirapine; 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, Masschusetts USA.
237.
Lallemant M, et al. Efficacy and safety of 1-month post-partum zidovudine and didanosine to prevent hiv-1 nevirapine resistance mutations following intrapartum single-dose nevirapine; 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
238.
Moorthy A, et al. Nevirapine resistance and breast-milk hiv transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype c hiv-infected infants. PLoS One. 2009;4:e4096. [PMC free article: PMC2606064] [PubMed: 19119321]
239.
McIntyre J, et al. Efficacy of short-course azt plus 3tc to reduce nevirapine resistance in the prevention of mother-to-child hiv transmission: A randomized clinical trial. PLoS Med. 2009;6:e1000172. [PMC free article: PMC2760761] [PubMed: 19859531]
240.
Eshleman S, et al. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of hiv-1. J Infect Dis. 2006;193:479–81. [PubMed: 16425125]
241.
Chaix M, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of hiv-1: Agence nationale de recherches sur le sida ditrame plus, abidjan, Côte d'Ivoire. J Infect Dis. 2006;193:482–87. [PubMed: 16425126]
Copyright © 2010, World Health Organization.

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: tni.ohw@snoissimrep).

Bookshelf ID: NBK138570

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...